Log in

Relevant bibliographies by topics / Biochemical markers ; Breast – Cancer – Molecular diagnosis

Contents

Journal articles
Dissertations / Theses
Books
Book chapters
Reports

Academic literature on the topic 'Biochemical markers ; Breast – Cancer – Molecular diagnosis'

Author: Grafiati

Published: 4 June 2021

Last updated: 1 February 2022

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the lists of relevant articles, books, theses, conference reports, and other scholarly sources on the topic 'Biochemical markers ; Breast – Cancer – Molecular diagnosis.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Journal articles on the topic "Biochemical markers ; Breast – Cancer – Molecular diagnosis"

1

El-Assal. "Early Diagnosis of Breast Cancer using Molecular, Biochemical and Pathological Markers." American Journal of Applied Sciences 8, no. 1 (2011): 1–8. http://dx.doi.org/10.3844/ajassp.2011.1.8.

Full text

APA, Harvard, Vancouver, ISO, and other styles

2

Lee, Ahwon, Yonggoo Kim, Kyungja Han, Chang Suk Kang, Hae Myung Jeon, and Sang In Shim. "Detection of Tumor Markers Including Carcinoembryonic Antigen, APC, and Cyclin D2 in Fine-Needle Aspiration Fluid of Breast." Archives of Pathology & Laboratory Medicine 128, no. 11 (2004): 1251–56. http://dx.doi.org/10.5858/2004-128-1251-dotmic.

Full text

Abstract:

Abstract Context.—The traditional triple test for breast cancer diagnosis is physical examination, mammography, and aspiration cytology. However, the accuracy of mammography on young women with nonatrophied breasts is poor compared with that for women older than 50 years, and additional methods for diagnosis of breast cancer are needed. Objective.—To investigate whether carcinoembryonic antigen (CEA), CA 15-3, and CA 125 concentrations in breast aspiration fluid are useful as breast cancer biochemical markers and whether APC and cyclin D2 gene promoter hypermethylation could be regarded as a b

APA, Harvard, Vancouver, ISO, and other styles

3

He, Qiuhong, Ray Z. Xu, Pavel Shkarin, et al. "Magnetic Resonance Spectroscopic Imaging of Tumor Metabolic Markers for Cancer Diagnosis, Metabolic Phenotyping, and Characterization of Tumor Microenvironment." Disease Markers 19, no. 2-3 (2004): 69–94. http://dx.doi.org/10.1155/2004/424395.

Full text

Abstract:

Cancer cells display heterogeneous genetic characteristics, depending on the tumor dynamic microenvironment. Abnormal tumor vasculature and poor tissue oxygenation generate a fraction of hypoxic tumor cells that have selective advantages in metastasis and invasion and often resist chemo- and radiation therapies. The genetic alterations acquired by tumors modify their biochemical pathways, which results in abnormal tumor metabolism. An elevation in glycolysis known as the “Warburg effect” and changes in lipid synthesis and oxidation occur. Magnetic resonance spectroscopy (MRS) has been used to

APA, Harvard, Vancouver, ISO, and other styles

4

Yazdani, Akram, and Hossein Akbari. "Association of CA 15-3 and CEA with Liver Metastases in Patients with Breast Cancer." Current Cancer Therapy Reviews 16, no. 4 (2020): 332–36. http://dx.doi.org/10.2174/1573394716666191216112938.

Full text

Abstract:

Objective: The liver is the second most common site of distant metastasis from breast cancer that is usually associated with poor prognosis and low quality of life in breast cancer patients. Therefore, the primary diagnosis of liver metastatic lesions in breast cancer patients is very important. In this study, the ability of biochemical markers CA153, CEA, and ALP to be used for prognostic liver metastasis in women with breast cancer was investigated. Methods: 306 women with breast cancer recorded between 2008 and 2012 were included. Serum concentrations of alkaline phosphatase (ALP), carcinog

APA, Harvard, Vancouver, ISO, and other styles

5

Kumar, Aniket, Ashis Kumar Ghosh, Sudhanshu Kumar Bharti, et al. "MALDI-TOF based Proteomics Analysis of Breast Cancer in Clinical Pathology: A Valuable Tool for Biomarker Identification." Science & Technology Journal 8, no. 1 (2020): 24–32. http://dx.doi.org/10.22232/stj.2020.08.01.02.

Full text

Abstract:

This study analyse the performance of tissue-based proteomics for early diagnosis of breast cancer for reducing its risk by identifying the causal factors. Breast cancer was induced by 7, 12-Dimethylbenz(a)anthracene (DMBA) in female albino mice followed by blood and tissue sample collection for biochemical and histological analysis. Total protein was isolated and quantified and peptides were detected by SDS-PAGE. For proteomics analysis and generation of peptide peaks, Matrix Assisted Laser Desorption/Ionization-Time of Flight-Mass Spectroscopy (MALDI-TOF-MS) was used and identification of un

APA, Harvard, Vancouver, ISO, and other styles

6

Hosseini Mojahed, Fatemeh, Amir Hossein Aalami, Vahid Pouresmaeil, Amir Amirabadi, Mahdi Qasemi Rad, and Amirhossein Sahebkar. "Clinical Evaluation of the Diagnostic Role of MicroRNA-155 in Breast Cancer." International Journal of Genomics 2020 (September 8, 2020): 1–13. http://dx.doi.org/10.1155/2020/9514831.

Full text

Abstract:

Aim. Biochemical markers, including microRNAs (miRs), may facilitate the diagnosis and prognosis of breast cancer. This study was aimed at assessing serum miR-155 expression in patients with breast cancer and receptors. Methods. This case-control study was conducted on 36 patients with breast cancer and 36 healthy individuals. After RNA extraction from the patient’s serum, cDNA was synthesized. The expression of miR-155 was measured using RT-qPCR. Demographic and histochemical data were extracted from patient documents. Data were analyzed using the Statistical Package for the Social Sciences (

APA, Harvard, Vancouver, ISO, and other styles

7

Zhang, Yuzhu, Huachao Li, Hongyan Zhang та ін. "A small molecule LN435a targeting TGFβR1 exerts promising antitumor effects on breast cancer." Journal of Clinical Oncology 39, № 15_suppl (2021): e15069-e15069. http://dx.doi.org/10.1200/jco.2021.39.15_suppl.e15069.

Full text

Abstract:

e15069 Background: Breast cancer has overtaken lung cancer as the most diagnosed cancer. Despite conventional treatment, metastases occur in 20-30% of patients, resulting in death. This study aims to screen of effective drugs by metastatic patient-derived organoid and the potential molecular mechanism. Methods: Breast Cancer patient-derived organoid (PDO) model was established from the patient who have multiple drug resistance, multiple visceral and contralateral breast metastases. The organoid morphologies was tested by hematoxylin-eosin (HE) staining and immunohistochemistry (IHC). Then, pha

APA, Harvard, Vancouver, ISO, and other styles

8

Jafari, Seyed Hamed, Zahra Saadatpour, Arash Salmaninejad, et al. "Breast cancer diagnosis: Imaging techniques and biochemical markers." Journal of Cellular Physiology 233, no. 7 (2018): 5200–5213. http://dx.doi.org/10.1002/jcp.26379.

Full text

APA, Harvard, Vancouver, ISO, and other styles

9

Al-Jassani, Mohammed J., Wasan K. Alwan, Ayad M. J. Almamoori, Maher M. Khadairi, and Saadi Mohammad Salh. "BIOCHEMICAL AND MOLECULAR MARKERS IN BREAST CANCER PATIENTS." Annals of Tropical Medicine and Public Health 22, no. 05 (2019): 41–49. http://dx.doi.org/10.36295/asro.2019.22055.

Full text

APA, Harvard, Vancouver, ISO, and other styles

10

Palma, M. A., and J. J. Body. "Usefulness of Bone Formation Markers in Breast Cancer." International Journal of Biological Markers 20, no. 3 (2005): 146–55. http://dx.doi.org/10.1177/172460080502000302.

Full text

Abstract:

The skeleton is the main site affected by metastases and breast cancer is the most frequent tumor to invade bone. The assessment of bone metastases is difficult and biochemical markers of bone formation (BFMs) could be a promising alternative. Although the essential role of osteoblasts in the metastatic process of bone destruction is now well established, little attention has been paid to BFMs. We conducted a Medline search for studies about BFMs in breast cancer. Our review allows us to conclude that BFMs have high specificity but low sensitivity for the diagnosis of bone metastases. The avai

APA, Harvard, Vancouver, ISO, and other styles

More sources

Dissertations / Theses on the topic "Biochemical markers ; Breast – Cancer – Molecular diagnosis"

1

Dawson, Sarah-Jane. "Molecular biomarkers in breast cancer." Thesis, University of Cambridge, 2011. http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.609742.

Full text

APA, Harvard, Vancouver, ISO, and other styles

2

Eaton, Michael Campbell. "Assessment of CD44 and K19 as markers for circulating breast cancer cells using immunobead RT-PCR /." Title page, table of contents and abstract only, 1997. http://web4.library.adelaide.edu.au/theses/09MD/09mde14.pdf.

Full text

APA, Harvard, Vancouver, ISO, and other styles

3

Puig, Vives Montserrat. "Breast cancer epidemiology: mammographic screening and molecular subtypes." Doctoral thesis, Universitat de Girona, 2015. http://hdl.handle.net/10803/289426.

Full text

Abstract:

The aim of this thesis is to carry out an in-depth study of various aspects of breast cancer epidemiology. Firstly, we have confirmed that DCIS incidence in Girona has increased over recent decades. Proportions of screen-detected cancers, interval cancers and non-screen-detected cancers during the start-up phase of the mammographic screening programme were found to be 42.2%, 5.8% and 52.2%, respectively. Secondly, we have found that luminal A-like was the most frequent subtype associated with the best survival rate, while triple-negative breast cancer was related to the lowest survival rate. I

APA, Harvard, Vancouver, ISO, and other styles

4

Ansari, Dominic O. "Raman-encoded nanoparticles for biomolecular detection and cancer diagnostics." Diss., Atlanta, Ga. : Georgia Institute of Technology, 2008. http://hdl.handle.net/1853/26664.

Full text

Abstract:

Thesis (Ph. D.)--Biomedical Engineering, Georgia Institute of Technology, 2009.<br>Committee Chair: Nie, Shuming; Committee Member: Parkos, Charles; Committee Member: Petros, John; Committee Member: Voit, Eberhard; Committee Member: Zhu, Cheng. Part of the SMARTech Electronic Thesis and Dissertation Collection.

APA, Harvard, Vancouver, ISO, and other styles

5

Tong, Chiu-hung, and 唐朝虹. "MiR-143 and its downstream targets: possible biomarkers for cervical cancer and precursors." Thesis, The University of Hong Kong (Pokfulam, Hong Kong), 2011. http://hub.hku.hk/bib/B46579436.

Full text

APA, Harvard, Vancouver, ISO, and other styles

6

Clavé, Safont Sergi. "Diagnòstic molecular de biomarcadors predictius en pacients amb càncer de pulmó de cèl·lula no petita." Doctoral thesis, Universitat de Barcelona, 2019. http://hdl.handle.net/10803/668281.

Full text

Abstract:

El càncer de pulmó de cèl·lula no petita (CPCNP) es pot definir a nivell molecular per les alteracions genètiques que es produeixen en múltiples oncogens, inclosos els reordenaments dels gens ALK i ROS1. Per optimitzar el maneig clínic, el perfil molecular ha d'estar disponible per a tots els pacients per tal de fer accessibles les teràpies dirigides mitjançant tractaments inhibidors específics. Des de 2011, el test estàndard per detectar els reordenaments d’ALK i ROS1 ha estat la hibridació in situ fluorescent (FISH) utilitzant sondes de trencament i més endavant es va estandarditzar la detec

APA, Harvard, Vancouver, ISO, and other styles

7

"Multiple biochemical markers for breast cancer." 1998. http://library.cuhk.edu.hk/record=b5889807.

Full text

Abstract:

by Yu Xiongwen.<br>Thesis (M.Sc.)--Chinese University of Hong Kong, 1998.<br>Includes bibliographical references (leaves 74-84).<br>Abstract also in Chinese.<br>Acknowledgments --- p.i<br>Abstract --- p.ii<br>List of Tables --- p.iii<br>List of Figures --- p.iv<br>Chapter Chapter 1 --- Introduction --- p.1<br>Chapter 1.1 --- Tumor Marker --- p.1<br>Chapter 1.1.1 --- General concept of tumor marker --- p.1<br>Chapter 1.1.2 --- Application of tumor marker --- p.2<br>Chapter 1.1.3 --- Limitation of tumor markers --- p.5<br>Chapter 1.2 --- Breast Cancer --- p.6<br>Chapter 1.2.1 --- Incid

APA, Harvard, Vancouver, ISO, and other styles

8

Liu, Jiangang. "MOLECULAR PROFILING IN BREAST CANCER AND TOXICOGENOMICS." 2011. http://hdl.handle.net/1805/2636.

Full text

Abstract:

Indiana University-Purdue University Indianapolis (IUPUI)<br>This dissertation presents a body of research that attempts to tackle the ‘overfitting’ problem for gene signature and biomarker development in two different aspects (mechanistically and computationally). In achievement of a deeper understanding of cancer molecular mechanisms, this study presents new approaches to derive gene signatures for various biological phenotypes, including breast cancer, in the context of well-defined and mechanistically associated biological pathways. We identified the pattern of gene expression in the cell

APA, Harvard, Vancouver, ISO, and other styles

9

Hardingham, Jennifer E. (Jennifer Elizabeth). "Molecular detection and significance of circulating colorectal cancer cells / Jennifer E. Hardingham." 1998. http://hdl.handle.net/2440/19379.

Full text

Abstract:

Bibliography: leaves 214-236.<br>xviii, 238 leaves : ill. (some col.) ; 30 cm.<br>Title page, contents and abstract only. The complete thesis in print form is available from the University Library.<br>Thesis (Ph.D.)--University of Adelaide, Dept. of Physiology, 1999

APA, Harvard, Vancouver, ISO, and other styles

Books on the topic "Biochemical markers ; Breast – Cancer – Molecular diagnosis"

1

(Editor), Jeffrey S. Ross, and Gabriel N. Hortobagyi (Editor), eds. Molecular Oncology of Breast Cancer. Jones & Bartlett Publishers, 2004.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

2

Hayes, Daniel F., and Giampietro Gasparini. Biomarkers in Breast Cancer. Humana, 2010.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

3

(Editor), Giampietro Gasparini, and Daniel F. Hayes (Editor), eds. Biomarkers in Breast Cancer (Cancer Drug Discovery and Development). Humana Press, 2005.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

4

Barh, Debmalya, and Mehmet Gunduz. Noninvasive Molecular Markers in Gynecologic Cancers. Taylor & Francis Group, 2015.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

5

Barh, Debmalya. Noninvasive Molecular Markers in Gynecologic Cancers. Taylor & Francis Group, 2019.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

6

Mark, Furth, Greaves M. F. 1941-, and Cold Spring Harbor Laboratory, eds. Molecular diagnostics of human cancer. Cold Spring Harbor Laboratory Press, 1989.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

7

Biomarkers in breast cancer: Molecular diagnostics for predicting and monitoring therapeutic effect. Humana Press, 2006.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

8

Giampietro, Gasparini, and Hayes Daniel 1951-, eds. Biomarkers in breast cancer: Molecular diagnostics for predicting and monitoring therapeutic effect. Humana Press, 2006.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

9

1922-, Dao Thomas L., Brodie Angela, Ip Clement, and Organ Systems Program (National Cancer Institute). Breast Cancer Working Group., eds. Tumor markers and their significance in the management of breast cancer: Proceedings of a workshop held in Bethesda, Maryland, March 6, 1985. Liss, 1986.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

10

Cassidy, Jim, Donald Bissett, Roy A. J. Spence OBE, Roy A. J. Spence OBE, Miranda Payne, and Gareth Morris-Stiff. Biomarkers and cancer. Oxford University Press, 2018. http://dx.doi.org/10.1093/med/9780199689842.003.0040.

Full text

Abstract:

Biomarkers and cancer defines these markers and outlines their role in diagnosis, prognosis, prediction of response, and response assessment of a variety of cancers. Established biomarkers are reviewed, and the potential for development of new biomarkers offered by the dramatic progress in both the understanding of molecular biology and the development of laboratory techniques is emphasised. The field of signal transduction has already proved fruitful, with identification of markers allowing successful targeted therapy in a range of cancers. Progress is anticipated also in tumour imaging, with

APA, Harvard, Vancouver, ISO, and other styles

Book chapters on the topic "Biochemical markers ; Breast – Cancer – Molecular diagnosis"

1

Koleckova, Marketa, Katherine Vomackova, and Zdenek Kolar. "Molecular Prognostic and Predictive Markers in Triple - Negative Breast Cancer." In Breast Cancer [Working Title]. IntechOpen, 2021. http://dx.doi.org/10.5772/intechopen.97282.

Full text

Abstract:

Triple-negative breast cancer (TNBC) is defined as a molecular subtype of breast cancer that lacks expression of hormone receptors (oestrogen and progesterone receptor) and HER2/neu/ErbB2 protein. It accounts for 15–20% of all invasive breast cancers. The occurrence of TNBC is often associated with younger age at the time of diagnosis and pre-menopausal status, early onset of menarche, higher body mass index (BMI) in the pre-menopausal period, race and ethnicity (African, Hispanic) and the presence of germline mutation in the BRCA1/2 genes or somatic mutation in the TP53 or PTEN genes. TNBCs are specific in its aggressive biological behaviour, shorter interval to disease progression and more frequent relapse within five years (19 to 40 months). The most of TNBCs are represented by high-grade invasive carcinomas of no special type (NST) with high proliferation index measured by Ki-67 nuclear expression, followed by metaplastic carcinomas, secretory carcinomas, and adenoid cystic carcinomas. Genetical and morphological heterogeneity inside TNBC is responsible for the higher frequency of primary and secondary resistance to systemic therapy. The scope of this chapter is to summarise the potential therapeutic agents involved in regulation of cell proliferation, migration, angiogenesis, apoptosis, gene expression and DNA damage or immune response. The insight into this issue is essential for the setting of the optimal chemotherapy regimen and targeted therapeutic strategy.

APA, Harvard, Vancouver, ISO, and other styles

2

"Osteosarcoma Cell Culture and Maintenance to Detect the Apoptotic Effect of Some Promising Compounds by Potent Markers viz. DNA." In Protocols used in Molecular Biology, edited by Asif Jafri, Juhi Rais, Sudhir Kumar, and Md Arshad. BENTHAM SCIENCE PUBLISHERS, 2020. http://dx.doi.org/10.2174/9789811439315120010014.

Full text

Abstract:

Osteosarcoma is the most common type of malignancy of bone and generally occurs among adolescent and young adults. Like the osteoblast cells of normal bone, osteosarcoma also forms the bone matrix, but the osteoid is not as strong as that of normal bones. Osteosarcoma is characterized by the production of weak or immature bones by the malignant cells. As the diagnosis of osteosarcoma is extremely poor, it suggests a critical need to develop some promising anti-osteosarcoma drugs to improve disease outcome. Many anti-cancer compounds induce apoptotic cell suicide via some potent cellular, molecular and biochemical markers. The cancer cell lines provide a valuable model system to study an extensive variety of cancer characteristics in the cell biology, genetics and chemotherapy or the impact of therapeutic molecules. The methods presented in this chapter describe the experimental technique used to culture the osteosarcoma cells for the documentation of DNA fragmentation and Caspase-3 activation associated with apoptosis.

APA, Harvard, Vancouver, ISO, and other styles

3

"Pathology." In Oxford Handbook for Medical School, edited by Kapil Sugand, Miriam Berry, Imran Yusuf, et al. Oxford University Press, 2019. http://dx.doi.org/10.1093/med/9780199681907.003.0028.

Full text

Abstract:

Pathology is the scientific study of disease, while clinical pathology is about integrating the morphological, biochemical, and molecular analyses with the clinical information provided to achieve a definite diagnosis. Its major subdivisions include histopathology, cytopathology, haematopathology, chemical pathology, and medical microbiology. Other disciplines include medical genetics, immunology, virology, toxicology, and forensic pathology. Histopathology involves studying tissue, such as biopsy specimens, to make a diagnosis, most commonly in the diagnosis of cancer and the chapter discusses grading and staging of cancers. The chapter also covers UK screening programmes for cervical, breast, and colon cancer. Haematological, skin, and cell specimens are also discussed, alongside other methods such as immunohistochemistry and immunofluorescence. Forensic pathology and criteria for referring a death to the coroner are also covered.

APA, Harvard, Vancouver, ISO, and other styles

Reports on the topic "Biochemical markers ; Breast – Cancer – Molecular diagnosis"

1

Lokshin, Anna. Integrated Development of Serum Molecular Markers for Early Diagnosis of Breast Cancer. Defense Technical Information Center, 2006. http://dx.doi.org/10.21236/ada462774.

Full text

APA, Harvard, Vancouver, ISO, and other styles

We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!